Yuhan Corporation
VC Fund
Seoul, South Korea
Yuhan Corporation is a VC fund in Seoul focused on Biotechnology and Health Care. Yuhan Co, Ltd. is a South Korean pharmaceutical and chemical company.
- Total investments:
- 24
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Yuhan Corporation invests in
Stages Yuhan Corporation invests in
Countries Yuhan Corporation invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series B
- $13M–$40B
- Series C
- $7.3M–$32M
- Corporate Round
- $2k–$12M
Investment Focus
Industry
- Biotechnology 9 (38%)
- Health Care 8 (33%)
- Pharmaceutical 5 (21%)
- Medical 4 (17%)
- Artificial Intelligence 4 (17%)
Stage
- Series B 6 (25%)
- Series C 4 (17%)
- Seed 3 (13%)
- Corporate Round 3 (13%)
- Series A 1 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Wook Je Cho
CEO
|
CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| J INTS BIO is a biotechnology company focused on the research and development of anticancer drugs and orphan medicines. The company develops targeted therapies for conditions such as non-small cell lung cancer and solid tumors. | $11.9M / Corporate Round / Mar 26, 2026 | ||
| Nobo Medicine is a clinical-stage biotech company focused on developing precision therapies for blood cancers and immune-related aging diseases. It uses biomarker-driven drug discovery and translational research to identify targeted treatments, aiming to improve outcomes in oncology and age-associated immune dysfunction through innovative,data-driven biomedical approaches. | $19.8M / Series C / Jul 28, 2025 | ||
| Kimcell & Gene is creating antibody treatments that target resistance. | Seed / Jun 20, 2025 | ||
| Progene is an R&D-focused biopharmaceutical development venture that has maintained continuous collaboration and partnerships with the top pharmaceutical companies. Progene’s platform technology is a multi-target fusion protein technology, and it aims to discover various new drug candidates using this technology and create value and achievecontinuous growth through joint development or external technology transfer. | $5.6M / Post-IPO Equity / Apr 17, 2025 | ||
| AIMEDBIO provides therapeutic solutions to patients with serious brain diseases. | $29.2M / Series B / Jul 31, 2024 | ||
| SB BIO Pharm is a company that provides quality healthcare services for the health of companion animals.SB Biopharm Co., Ltd. is a biopharmaceutical company specializing in the development and production of veterinary medicines, quasi-drugs, supplementary feeds, etc. by researching the nutrition of companion animals. They operate a professionaldiagnosis center that can check the health of companion animals and an independent nutrition research institute, equipped with both veterinary medicine and nutrition. | $4.6M / Corporate Round / Mar 13, 2024 | ||
| ImmuneOncia is an immuno-oncology-centric biopharmaceutical company. Established in 2016 as a joint venture company between Yuhan (51%) and Sorrento (49%), ImmuneOncia will leverage both companies’ expertise in drug development and antibody engineering. Our mission is to bring safe, effective, and novel immunotherapies to oncology patientsworld-wide. ImmuneOncia’s portfolio includes diverse immune checkpoint antibodies; the lead antibody IMC-001 is in Phase 1 clinical trial. Yuhan Corporation is a South Korea-based healthcare company founded in 1926. The company has positioned itself as one of the top pharmaceutical companies in terms of market cap and sales revenue in Korea. The core business consists of primary & specialty care, dietary supplements, household & animal care, and contract manufacturing of active pharmaceutical ingredients. It has a number of subsidiaries and a global presence in the form of joint ventures with Janssen (Belgium), the Clorox Company (USA), and Kimberly-Clark Corporation (USA). Yuhan (000100:KS) is a publicly-listed company traded on the Korea Stock Exchange. | $8.9M / Venture - Series Unknown / Jan 12, 2024 | ||
| J INTS BIO is a biotechnology company focused on the research and development of anticancer drugs and orphan medicines. The company develops targeted therapies for conditions such as non-small cell lung cancer and solid tumors. | $1.6M / Corporate Round / Nov 29, 2023 | ||
| AinB is a biotechnology startup focused on applying artificial intelligence (AI) to the discovery and development of novel biologic drugs, particularly antibody therapeutics. By combining scientific expertise in antibody therapeutics with advanced AI capabilities, the company aims to develop innovative treatments more efficiently and strengthenKorea’s competitiveness in the global biopharmaceutical industry. | Seed / Mar 15, 2023 | ||
| Nobo Medicine is a clinical-stage biotech company focused on developing precision therapies for blood cancers and immune-related aging diseases. It uses biomarker-driven drug discovery and translational research to identify targeted treatments, aiming to improve outcomes in oncology and age-associated immune dysfunction through innovative,data-driven biomedical approaches. | $7.8M / Series B / Dec 21, 2022 | ||
| See all 24 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Yuhan Corporation invest in?
Yuhan Corporation invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 24 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Yuhan Corporation invest in?
Yuhan Corporation typically joins rounds of $13M–$40B at Series B, $7.3M–$32M at Series C and $2k–$12M at Corporate Round. These are whole funding-round sizes, not Yuhan Corporation's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Yuhan Corporation took part in.
How do I contact Yuhan Corporation?
Public channels for Yuhan Corporation include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Yuhan Corporation?
The team at Yuhan Corporation includes Wook Je Cho (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
